Moa Technology
Moa Technology Raises £22.2M Series C for Novel Herbicide Discovery
Moa Technology announced £22.2M in Series C financing on July 23, 2026. Moa Technology raised a £22.2 million Series C co-led by Oxford Science Enterprises and Supernova Invest to advance its novel mode of action herbicide programmes.
Round details
The financing includes backing from Oxford Science Enterprises, Supernova Invest, Agri Investment Fund, Infinity Investment Partners, Magdalen College Oxford, Lansdowne Partners, Parkwalk. The company did not publish a valuation with the announcement.
- Round: Series C
- Capital announced: £22.2M
How the company plans to use the capital
Moa said the Series C funding will bring its three most advanced programmes significantly closer to commercialisation, build its pipeline of early-stage novel mode of action herbicides and further develop the Moa Amplifiers programme. The company said the new equity will be supplemented by upfront and milestone payments from current and future industry partners.
Why this matters for GTM teams
The round was co-led by existing investor Oxford Science Enterprises and new investor Supernova Invest, and Moa said the new equity investment will be supplemented by upfront and milestone payments from current and future industry partners.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Moa Technology Series C announcement.
Company Info
Investors (7)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


